Skip to content
Menu Close
  • About us
    • Our Journey
    • Board of Directors
    • Leadership
    • Governance
    • Manufacturing
    • R&D
  • Innovation
    • Overview
    • Pipeline
    • Partnerships
  • Products
    • Portfolio
    • Top Products
  • Responsibility
    • Corporate Social Responsibility
    • Sustainability
  • Investors
    • Financials
    • Disclosures under Regulation 46 of SEBI LODR
    • Investor Resources
    • Other Announcements
  • News
    • Press Release
    • Media Library
  • Careers
    • Life at Glenmark
    • Glenmark Center for Learning
    • Join Us
  • About us
    • Our Journey
    • Board of Directors
    • Leadership
    • Governance
    • Manufacturing
    • R&D
  • Innovation
    • Overview
    • Pipeline
    • Partnerships
  • Products
    • Portfolio
    • Top Products
  • Responsibility
    • Corporate Social Responsibility
    • Sustainability
  • Investors
    • Financials
    • Disclosures under Regulation 46 of SEBI LODR
    • Investor Resources
    • Other Announcements
  • News
    • Press Release
    • Media Library
  • Careers
    • Life at Glenmark
    • Glenmark Center for Learning
    • Join Us
Menu Close
  •  Global
    • US 
    • India 
    • Europe
    • Latin America
    • ROW
      • Asia
        • Malaysia
      • Australia
      • Me & Africa
      • Russia & CIS
  •  Global
    • US 
    • India 
    • Europe
    • Latin America
    • ROW
      • Asia
        • Malaysia
      • Australia
      • Me & Africa
      • Russia & CIS
  • Global

More results...

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
page
Connect with Us
  • About us
    • Our journey
    • Board of Directors
    • Leadership Team
    • Governance
    • Manufacturing
    • R&D Locations
  • Innovation
    • Overview
    • Pipeline
    • Partnerships
  • Products
    • Portfolio
    • Top Products
  • Responsibility
    • Corporate Social Responsibility
    • Sustainibility
  • Investors
    •  Financials
      • Quarterly Results
      • Investor Presentations
      • Annual Report
    • Disclosure under Regulation 46 of SEBI (LODR) Regulations, 2015
    • Investor Resources
    •  Other announcements
      • 2026
      • 2025
      • 2024
      • 2023
  • News
    •  Press Release
      • 2026
      • 2025
      • 2024
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
    • Media Library
  • Careers
    • Life at Glenmark
    • Glenmark Center for Learning
    • Join Us
  • Contact Us
  • IGI
  • Global
  • About us
    • Our journey
    • Board of Directors
    • Leadership Team
    • Governance
    • Manufacturing
    • R&D Locations
  • Innovation
    • Overview
    • Pipeline
    • Partnerships
  • Products
    • Portfolio
    • Top Products
  • Responsibility
    • Corporate Social Responsibility
    • Sustainibility
  • Investors
    •  Financials
      • Quarterly Results
      • Investor Presentations
      • Annual Report
    • Disclosure under Regulation 46 of SEBI (LODR) Regulations, 2015
    • Investor Resources
    •  Other announcements
      • 2026
      • 2025
      • 2024
      • 2023
  • News
    •  Press Release
      • 2026
      • 2025
      • 2024
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
    • Media Library
  • Careers
    • Life at Glenmark
    • Glenmark Center for Learning
    • Join Us
  • Contact Us
  • IGI
  • Global

Subsidiary Financials FY21-22

Financials Close
  • Quarter Results
  • Investor Presentation
  • Annual Report
  • Quarter Results
  • Investor Presentation
  • Annual Report
Subsidiary Close
  • 2024 – 25
  • 2023 – 24
  • 2022 – 23
  • 2021 – 22
  • 2020 – 21
  • 2019 – 20
  • 2018 – 19
  • 2017 – 18
  • 2024 – 25
  • 2023 – 24
  • 2022 – 23
  • 2021 – 22
  • 2020 – 21
  • 2019 – 20
  • 2018 – 19
  • 2017 – 18

Glenmark Pharmaceuticals (Australia) Pty Limited

Glenmark Holding SA La Chaux-de-Fonds

Glenmark-Pharmaceuticals Ecuador S.A.

Glenmark Pharmaceuticals Singapore Pte. Ltd.

Glenmark Pharmaceuticals Europe Ltd., U.K.

Glenmark Life Sciences Limited

Glenmark Pharmaceuticals Malaysia Sdn Bhd

Glenmark Pharmaceuticals (Nigeria) Ltd

Glenmark Philippines Inc.

Glenmark Pharmaceuticals S.R.O.

Glenmark Pharmaceuticals SK, S.R.O.

Glenmark Pharmaceuticals Peru SAC

Ichnos Sciences SA

Glenmark Pharmaceuticals Inc.

Glenmark Uruguay S.A.

Glenmark Pharmaceuticals Venezuela, C.A

Glenmark Dominicana SRL

Glenmark Pharmaceuticals FZE

Glenmark South Africa (pty) Ltd

Glenmark Pharmaceuticals South Africa (pty) Ltd

Glenmark Pharmaceuticals (Thailand) Co. Ltd

Glenmark Pharmaceuticals B.V.

Glenmark Arzneimittel Gmbh

Glenmark Pharmaceuticals Kenya Ltd

Viso Farmaceutica S.L., Spain

Glenmark Pharmaceuticals Distribution s.r.o.

Glenmark Pharmaceuticals Nordic AB

GLENMARK PHARMACEUTICALS SP. Z O.O.

Subsidiary Financials

  • 2024 – 25
  • 2023 – 24
  • 2022 – 23
  • 2021 – 22
  • 2020 – 21
  • 2019 – 20
  • 2018 – 19
  • 2017 – 18

Glenmark Pharmaceuticals Ltd. is a research‐led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology.

Linkedin-in Instagram Youtube

About us

  • Our Journey
  • Board of Directors
  • Leadership
  • Governance
  • Manufacturing
  • R&D

Innovation

  • Overview
  • Pipeline
  • Partnerships

Products

  • Portfolio
  • Top Brands

Responsibility

  • Corporate Social Responsibility
  • Sustainability

Investors

  • Financials
  • Disclosures under Regulation 46
    of SEBI LODR
  • Investor Resources
  • Other announcements

News

  • Press Release
  • Media Library

Careers

  • Life at Glenmark
  • Glenmark Centre for Learning
Join Us

CAUTION NOTICE REGARDING FRAUDULENT RECRUITMENT

This is to notify to the public that certain unscrupulous persons, purporting to be part of and/or being authorised by the human resources department of Glenmark Pharmaceuticals Limited (“Glenmark”) are fraudulently offering jobs via certain websites/or through telephone calls, SMS or fake letters and asking the prospective job aspirants to appear for a face-to-face interview for a job opening with Glenmark and/or to pay a fee for securing a job with Glenmark. We wish to caution the public that Glenmark does not collect any monies or any other valuables as a pre or post-employment requirement.

Click Here to Know More        Click Here to Join Us

Download Factsheet
  • Privacy Portal
  • Terms & Conditions
  • Report a Concern
  • Report an Adverse Event
  • Investigator Initiated Trials
© 2026 Glenmark Pharmaceuticals Ltd. All Rights Reserved.
  • About Us
  • Innovation
  • Products
  • Responsibility
  • Investors
  • News
  • Careers
  • Terms & Conditions
  • Report a Concern
  • Report an Adverse Event
  • Investigator Initiated Trials
  • Disclaimer
  • Privacy Portal
Download Factsheet
Linkedin-in Instagram Youtube
© 2026 Glenmark Pharmaceuticals Ltd.
All Rights Reserved.
  • About us
    • Our journey
    • Board of Directors
    • Leadership Team
    • Governance
    • Manufacturing
    • R&D Locations
  • Innovation
    • Overview
    • Pipeline
    • Partnerships
  • Products
    • Portfolio
    • Top Products
  • Responsibility
    • Corporate Social Responsibility
    • Sustainibility
  • Investors
    •  Financials
      • Quarterly Results
      • Investor Presentations
      • Annual Report
    • Disclosure under Regulation 46 of SEBI (LODR) Regulations, 2015
    • Investor Resources
    •  Other announcements
      • 2026
      • 2025
      • 2024
      • 2023
  • News
    •  Press Release
      • 2026
      • 2025
      • 2024
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
    • Media Library
  • Careers
    • Life at Glenmark
    • Glenmark Center for Learning
    • Join Us
  • Contact Us
  • IGI
  • Global
Type your search

CAUTION NOTICE REGARDING FRAUDULENT RECRUITMENT

This is to notify to the public that certain unscrupulous persons, purporting to be part of and/or being authorised by the human resources department of Glenmark Pharmaceuticals Limited (“Glenmark”) are fraudulently offering jobs via certain websites/or through telephone calls, SMS or fake letters and asking the prospective job aspirants to appear for a face-to-face interview for a job opening with Glenmark and/or to pay a fee for securing a job with Glenmark. We wish to caution the public that Glenmark does not collect any monies or any other valuables as a pre or post-employment requirement.

Click Here to Know More        Click Here to Join Us